MedTrace Logo

Effectiveness of Bisacodyl Suppository Agent for Dose Reduction of Low Dose PEG

NCT03849196 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 168

Last updated 2019-02-21

No results posted yet for this study

Summary

Proper bowel cleansing before colonoscopy is an important factor to increase the detection rate of lesions. Low volume polyethylene glycol (PEG) plus ascorbic (PEG-Asc) has reduced the dosage of previous bowel preparation agent, but it still presents discomfort to patients. The aim of this study was to confirm the efficacy and convenience of volume reduction of PEG-Asc by adding bisacodyl suppository at the same day by compared with conventional 2L PEG-Asc.

Conditions

  • Bowel Preparation

Interventions

DRUG

2L PEG-Asc

PEG-Asc powder

DRUG

Bisacodyl 10Mg Suppository

bisacodyl 10 mg suppository

DRUG

1L PEG-Asc

PEG-Asc powder

Sponsors & Collaborators

  • Samsung Medical Center

    lead OTHER

Principal Investigators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-07-31
Primary Completion
2018-01-30
Completion
2018-01-30

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03849196 on ClinicalTrials.gov